Mild asthma: from paradoxes to therapy optimization
Exacerbations of bronchial asthma are specific not only for severe, but also for mild disease course. Analysis of the causes revealed paradoxes in the treatment that contribute to the uncontrolled course of mild asthma. A promising direction is the use of combination drugs containing a early-onset beta-2-agonist and inhaled glucocorticosteroid, which can significantly improve adherence to treatment and significantly improve control and reduce the number of exacerbations. The review discusses in detail the merits of the combination drug SabaComb, its place in the recommendations for the treatme... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2018 |
| Reihe/Periodikum: | Медицинский совет, Vol 0, Iss 15, Pp 38-42 (2018) |
| Verlag/Hrsg.: |
Remedium Group LLC
|
| Schlagwörter: | mild asthma / asthma control / adherence to treatment / sabacomb / Medicine / R |
| Sprache: | Russian |
| Permalink: | https://search.fid-benelux.de/Record/base-29234233 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://doi.org/10.21518/2079-701X-2018-15-38-42 |
Exacerbations of bronchial asthma are specific not only for severe, but also for mild disease course. Analysis of the causes revealed paradoxes in the treatment that contribute to the uncontrolled course of mild asthma. A promising direction is the use of combination drugs containing a early-onset beta-2-agonist and inhaled glucocorticosteroid, which can significantly improve adherence to treatment and significantly improve control and reduce the number of exacerbations. The review discusses in detail the merits of the combination drug SabaComb, its place in the recommendations for the treatment of mild asthma.